

## REMARKS

Prior to examination on the merits, Applicants respectfully request entry of the above amendments to the specification and claims. Claims 1-18 have been canceled and new claims 19-26 have been added. Support for new claims 19-26 can be found throughout the specification and claims as originally filed in the parent application. Support for the adjuvants of claims 22-25 can be found, for example, at the disclosure from page 82, line 15 to page 83, line 9. The above amendments to the specification are made solely to correct a typographical error and do not constitute new matter. More particularly, it would be readily understood on the part of the skilled artisan, upon review of the subject specification and sequence listing, that SEQ ID NO: 139 represents the polypeptide sequence of a Chlamydia protein known as CT622, while SEQ ID NO: 140 represents the polypeptide sequence of a Chlamydia protein known as CT875.

The Commissioner is authorized to charge any additional fees due by way of this Amendment, or credit any overpayment, to our Deposit Account No. 19-1090.

All of the claims remaining in the application are believed to be in condition for allowance. Favorable consideration is respectfully requested.

Respectfully submitted,

SEED Intellectual Property Law Group PLLC



Jeffrey Hundley, Ph.D., Patent Agent  
Registration No. 42,676

JEH:tt

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

447168\_1.DOC